New approaches to pharmacotherapy for rheumatoid arthritis: perspective for use of tocilizumab (monoclonal antibodies to interleukin-6 receptor)
Nasonov, E.L.
Terapevticheskii Arkhiv 82(5): 64-71
2010
ISSN/ISBN: 0040-3660 PMID: 20597275 Document Number: 646570
The author considers a role of interleukin-6 (IL-6) as a cytokine, elevated concentrations of which in serum and synovial fluid correlate with the activity of articular inflammation and the development of systemic manifestations in rheumatoid arthritis (RA). There is strong evidence suggesting that effective treatment with gene-engineering biologicals causes a reduction in IL-6 concentrations. Detailed information is given on the novel drug tocilizumab that is humanized monoclonal antibodies (IgG) and the first and only agent that is able to suppress IL-6-dependent inflammatory reactions and is permitted for use in RA.
Document emailed within 1 workday
Related Documents
Arman, A.; Yilmaz, B.; Coker, A.; Inanc, N.; Direskeneli, H. 2006: Interleukin-1 receptor antagonist (IL-1RN) and interleukin-1B gene polymorphisms in Turkish patients with rheumatoid arthritis Clinical and Experimental Rheumatology 24(6): 643-648Reed, J.C.; Tadmori, W.; Kamoun, M.; Koretzky, G.; Nowell, P.C. 1985: Suppression of interleukin 2 receptor acquisition by monoclonal antibodies recognizing the 50 KD protein associated with the sheep erythrocyte receptor on human T lymphocytes Journal of Immunology 134(3): 1631-1639
Coaccioli, S.; Pinoca, F.; Giuliani, M.; Landucci, P.; Sabatini, C.; Puxeddu, A. 2007: Definition of adult-onset rheumatoid arthritis from elderly-onset rheumatoid arthritis by studying T-lymphocyte subpopulations, their soluble receptors and soluble receptor of interleukin-2 La Clinica Terapeutica 158(4): 303-306
Aita, T.; Yamamura, M.; Kawashima, M.; Okamoto, A.; Iwahashi, M.; Yamana, J.; Makino, H. 2004: Expression of interleukin 12 receptor (IL-12R) and IL-18R on CD4+ T cells from patients with rheumatoid arthritis Journal of Rheumatology 31(3): 448-456
Juhl, P.; Thudium, C.S.; Gudmann, N.S.; Karsdal, M.A.; Bay-Jensen, A.-C.; Siebuhr, A.S. 2018: IL-6 receptor inhibition modulates type IIi collagen and C-reactive protein degradation in rheumatoid arthritis patients with an inadequate response to anti-tumour necrosis factor therapy: analysis of connective tissue turnover in the tocilizumab RADIATE study Clinical and Experimental Rheumatology 36(4): 568-574
Brandão, F.M.; Coelho, P.; Pinto, P.; Combe, B. 2010: Tocilizumab - a new step in rheumatoid arthritis treatment Acta Reumatologica Portuguesa 35(3): 302-312
Grover, S.; Tandon, S.; Misra, R.; Aggarwal, A. 2006: Interleukin-1 receptor antagonist gene polymorphism in patients with rheumatoid arthritis in India Indian Journal of Medical Research 123(6): 815-820
Van Herwaarden, N.; Herfkens-Hol, S.; van der Maas, A.; van den Bemt, B.J.F.; van Vollenhoven, R.F.; Bijlsma, J.W.J.; den Broeder, A.A. 2014: Dose reduction of tocilizumab in rheumatoid arthritis patients with low disease activity Clinical and Experimental Rheumatology 32(3): 390-394
Spertini, F.ço. 2017: Hope for chronic inflammatory diseases : the anti-IL-6 receptor monoclonal antibody tocilizumab Revue Medicale Suisse 13(544-545): 20-22
Meijer, C.J.; de Graaff-Reitsma, C.B.; Lafeber, G.J.; Cats, A. 1982: In situ localization of lymphocyte subsets in synovial membranes of patients with rheumatoid arthritis with monoclonal antibodies Journal of Rheumatology 9(3): 359-365
Duke, O.; Panayi, G.S.; Janossy, G.; Poulter, L.W. 1982: An immunohistological analysis of lymphocyte subpopulations and their microenvironment in the synovial membranes of patients with rheumatoid arthritis using monoclonal antibodies Clinical and Experimental Immunology 49(1): 22-30
Manfredi, A.; Sebastiani, M.; Cassone, G.; Colaci, M.; Sandri, G.; Ferri, C. 2018: Tocilizumab for the treatment of patients with rheumatoid arthritis and interstitial lung diseases: a case series Clinical and Experimental Rheumatology 36(2): 342
Boiardi, L.; Macchioni, P.; Salvarani, C.; Rossi, F.; Casadei-Maldini, M.; Mancini, R.; Beltrandi, E.; Portioli, I. 1994: Serum soluble interleukin-2 receptor levels in rheumatoid arthritis: correlation with clinical and immunological parameters and with the response to auranofin treatment Clinical and Experimental Rheumatology 12(4): 357-362
Fleishmann, R.M. 2002: Safety of anakinra, a recombinant interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis and comparison to anti-TNF-alpha agents Clinical and Experimental Rheumatology 20(5 Suppl 27: S35-S41
Avdeev, A.S.; Novikov, A.A.; Aleksandrova, E.N.; Panasiuk, E.I.; Nasonov, E.L. 2014: The importance of cytokine profile characteristics for evaluating the therapeutic effectiveness of monoclonal antibodies against IL-6 receptors in patients with rheumatoid arthritis Klinicheskaia Meditsina 92(1): 28-34
Di Matteo, L.; D'Incecco, V.; Evangelista, L.; Castiglione, C.; Consoli, G. 1985: Evaluation of lymphocyte subpopulations using monoclonal antibodies in patients with rheumatoid arthritis undergoing treatment with a new gold salt (auranofin) Bollettino della Societa Italiana di Biologia Sperimentale 61(5): 777-781
Agius, M.A.; Geannopoulos, C.J.; Fairclough, R.H.; Richman, D.P. 1988: Monoclonal anti-idiotopic antibodies against myasthenia-inducing anti-acetylcholine receptor monoclonal antibodies. Preponderance of nonparatope-directed antibodies affecting antigen binding Journal of Immunology 140(1): 62-68
Terenzi, R.; Santoboni, G.; Bartoloni, E.; Alunno, A.; Luccioli, F.; Gerli, R. 2015: Correlation between clinimetric approach and German US7 score in rheumatoid arthritis patients treated with tocilizumab: a pilot study Clinical and Experimental Rheumatology 33(3): 445
Ohtsuka, K.; Yasunami, Y.; Ikehara, Y.; Nagai, T.; Kodama, S.; Maki, T.; Tomita, A.; Abo, T.; Ikeda, S. 1997: Expansion of intermediate T cell receptor cells expressing interleukin-2 receptor alpha- beta+, CD8alpha+ beta+, and lymphocyte function-associated antigen-1+ in the liver in association with intrahepatic islet xenograft rejection from rat to mouse: prevention of rejection with anti-interleukin-2 receptor beta monoclonal antibody treatment Transplantation 64(4): 633-639
Kuuliala, A.; Leirisalo-Repo, M.; Möttönen, T.; Hannonen, P.; Nissilä, M.; Kautiainen, H.; Korpela, M.; Julkunen, H.; Hakola, M.; Repo, H. 2005: Serum soluble interleukin-2 receptor predicts early remission in patients with recent-onset rheumatoid arthritis treated with a single disease-modifying antirheumatic drug Clinical and Experimental Rheumatology 23(2): 243-246